Laboratory Safety of Dupilumab in Moderate‐to‐severe Atopic Dermatitis: Results From Three Phase III Trials ( LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS )
British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.18434
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Wiley